Initial public offerings scheduled to debut next week

This is an archived article that was published on sltrib.com in 2014, and information in the article may be outdated. It is provided only for personal research purposes and may not be reprinted.

New York • The following is a list of initial public offerings planned for the week of July 28:

Angion Biomedica Corp. - Uniondale, N.Y., 2.7 million shares, priced $10 to $12, managed by Aegis Capital. Proposed Nasdaq Capital Market symbol ANGN. Business: Developing therapies for injured organs that trigger the body's natural regeneration.

Auris Medical Holding AG - Zug, Switzerland, 6.9 million common shares, priced $10 to $12, managed by Jefferies, and Leerink Partners. Proposed Nasdaq symbol EARS. Business: Biotech developing treatments for tinnitus and other inner ear disorders.

Avalanche Biotechnologies Inc. - Menlo Park, Calif., 5.4 million shares, priced $13 to $15, managed by Jefferies, Cowen, and Piper Jaffray. Proposed Nasdaq symbol AAVL. Business: Early-stage biotech developing a gene therapy for wet AMD.

Bio Blast Pharma Ltd. - Tel Aviv, Israel, 3.3 million ordinary shares, priced $11 to $13, managed by Oppenheimer, and Roth Capital. Proposed Nasdaq Capital Market symbol ORPN. Business: Biotech developing treatments for rare and ultra-rare genetic diseases.

Catalent Inc. - Somerset, N.J., 42.5 million shares, priced $19 to $22, managed by Morgan Stanley, J.P. Morgan, and BofA Merrill Lynch. Proposed NYSE symbol CTLT. Business: Global provider of oral, injectable and respiratory drug delivery technologies.

FCB Financial Holdings Inc. - Weston, Fla., 8.7 million shares, priced $24 to $27, managed by Deutsche Bank, J.P. Morgan, and BofA Merrill Lynch. Proposed NYSE symbol FCB. Business: Consolidation of 54 failed and acquired banks in Miami and coastal Florida.

HealthEquity Inc. - Draper, Utah, 9.1 million shares, priced $10 to $12, managed by J.P. Morgan, and Wells Fargo. Proposed Nasdaq symbol HQY. Business: Offers an integrated platform for managing health savings accounts.

Lantheus Holdings Inc. - North Billerica, Mass., 9.3 million shares, priced $12 to $15, managed by Citigroup, and Jefferies. Proposed Nasdaq symbol LNTH. Business: Sells medical imaging agents used in the diagnosis of cardiovascular diseases.

Loxo Oncology Inc. - Stamford, Conn., 4.4 million shares, priced $12 to $14, managed by Cowen & Co., and Stifel. Proposed Nasdaq symbol LOXO. Business: Biotech developing small molecule therapeutics to treat solid tumors.

Macrocure Ltd. - Petach Tikva, Israel, 5.4 million ordinary shares, priced $13 to $15, managed by Credit Suisse, and Jefferies. Proposed Nasdaq symbol MCUR. Business: Late-stage biotech developing white blood cell injections to treat hard-to-heal wounds.

Marinus Pharmaceuticals Inc. - New Haven, Conn., 4 million shares, priced $12 to $14, managed by Stifel, and JMP Securities. Proposed Nasdaq symbol MRNS. Business: Early-stage biotech developing an add-on therapy for epilepsy.

Mobileye N.V. - Jerusalem, Israel, 27.8 million ordinary shares, priced, $17 to $19, managed by Goldman Sachs, Morgan Stanley, and Deutsche Bank. Proposed NYSE symbol MBLY. Business: Provider of camera-based technology to avoid automobile collisions.

SIRVA Inc. - Oakbrook Terrace, Ill., 11.6 million shares, priced $15 to $17, managed by Morgan Stanley, Goldman Sachs, and J.P. Morgan. Proposed Nasdaq symbol SRVA. Business: Provides domestic and international relocation services for employees.

Synchrony Financial - Stamford, Conn., 125 million shares, priced $23 to $25, managed by Goldman Sachs, J.P. Morgan, and Citigroup. Proposed NYSE symbol SYF. Business: Spinoff of GE's private label credit card and consumer finance business.

Tobira Therapeutics Inc. - San Francisco, 4.6 million shares, priced $12 to $14, managed by BMO Capital Markets, JMP Securities, and Oppenheimer. Proposed Nasdaq symbol TBRA. Business: Biotech developing an immunotherapy treatment for liver disease (NASH) and HIV.

Transocean Partners LLC - Aberdeen, U.K., 17.5 million common units, priced $19 to $21, managed by Morgan Stanley, Barclays, and Citigroup. Proposed NYSE symbol RIGP. Business: LLC formed by Transocean to own three deepwater rigs in the Gulf of Mexico.

Vascular Biogenics Ltd. - Or Yehuda, Israel, 5.4 million ordinary shares, priced $13 to $15, managed by Deutsche Bank, and Wells Fargo. Proposed Nasdaq sybol VBLX. Business: Biotech developing gene therapies for certain cancers and inflammatory diseases.

VTTI Energy Partners LP - London, U.K., 17.5 million common units, priced $19 to $21, managed by Citigroup and J.P. Morgan. Proposed NYSE symbol VTTI. Business: Owns, operates, develops and acquires refined petroleum product and crude oil terminaling and related energy infrastructure assets.

Westlake Chemical Partners LP - Houston, 11.3 million common units, priced $19 to $21, managed by Barclays, UBS, and BofA Merrill Lynch. Proposed NYSE symbol WLKP. Business: Ethylene producer spun out of Westlake Chemical Corporation.

Zosano Pharma Corp. - Fremont, Calif., 6.4 million shares, priced $10 to $12, managed by Wedbush PacGrow, Ladenburg Thalmann, and Roth Capital. Proposed Nasdaq symbol ZSAN. Business: Biotech developing a transdermal delivery system to treat osteoporosis.

Sources include Renaissance Capital (http://www.renaissancecapital.com) and SEC filings